《艾滋病患者高活性抗逆转录病毒治疗相关的免疫重建炎性综合征的发病机制》

  • 来源专题:艾滋病防治
  • 编译者: 门佩璇
  • 发布时间:2014-09-26
  • 本研究探讨了艾滋病患者接受高活性抗逆转录病毒疗法 (HAART) 后免疫重建炎症反应综合征 (IRIS) 的免疫发病机制。该项前瞻性队列研究共纳入了238例接受了最初的HAART治疗的艾滋病患者。分别于研究基线时、接受HAART12周、24周后和出现IRIS时采集患者的血样。通过流式细胞仪或酶联免疫吸附法分别测定淋巴细胞亚群、Th1和Th2细胞因子、IL-7的水平。238例患者中,有47例发生了IRIS。在初始治疗后的24周后,出现IRIS和未出现IRIS患者的初始、记忆和活化CD4 + 和 CD8 + 细胞的比例没有显著差异。出现IRIS的患者组CD4 + CD25 + Foxp3 + 调节T细胞的比例在治疗前,治疗后12周、24周和出现IRIS时均明显低于未出现IRIS组的比例。此外,在治疗后4周和IRIS出现时,IRIS组的IL-2和IFN-γ水平均显著高于未出现IRIS组;IL-4和IL-10水平则明显低于未出现IRIS组。血浆IL-7水平随着HAART治疗的开展逐渐降低,且在所有的时间点上,IRIS组的IL-7水平均显著高于另一组。研究结果提示,Th1/Th2、持续降低的CD4 + CD25 + Fox3 + 比例和高IL-7水平可能是接受HAART治疗患者出现IRIS疾病进展的关键因素。

相关报告
  • 《合并HIV机会感染的HIV感染患者的即时和延迟抗逆转录病毒治疗:一项前瞻性随机开放的多中心研究》

    • 来源专题:重大疾病防治
    • 编译者:门佩璇
    • 发布时间:2019-11-20
    • 近日,来自德国汉堡大学医学中心传染病研究所的Guido Schafer等研究者开展的一项前瞻性随机开放的多中心研究,评估了晚期合并胆囊虫肺炎(PCP)或弓形虫脑炎(TE)等机会性感染(OI)的HIV感染者立即或延迟开展抗逆转录病毒治疗的临床结局。其研究结果于11月15日发表在《艾滋病研究与治疗》期刊上。 研究中,患者被随机分为立即治疗组(OI治疗开始后7天内开始抗逆转录病毒治疗)和延迟治疗组(完成OI治疗后开始抗逆转录治疗)。所有患者随访24周。比较临床进展率(死亡、新发或复发性机会感染(OI)和其他4个临床终末点),使用联合首要结局指标。次要终点为OI治疗完成后的住院率、免疫重建炎性综合征(IRIS)的发生率、病毒学和免疫学结果等。 共入组61例,其中TE11例,PCP50例。两治疗组之间首要结局指标和次要结局指标上均无显著差异。病毒学和免疫学结果,死亡事件和IRIS发生率等均无显著差异。 该研究结果揭示,HIV感染者立即启动一个利托那韦增强的蛋白酶抑制剂和两个核苷逆转录酶抑制剂的抗逆转录病毒治疗是安全的,对IRIS发病率、疾病进展没有影响,对免疫学和病毒学结果、生活质量等也没有负面影响。
  • 《英国艾滋病患者高活性抗逆转录病毒疗法的多中心群组研究》

    • 来源专题:艾滋病防治
    • 编译者:李越
    • 发布时间:2005-04-14
    • Objectives To investigate whether there is evidence that an increasing proportion of HIV infected patients is starting to experience increases in viral load and decreases in CD4 cell count that are consistent with exhaustion of available treatment options. Design Multicentre cohort study. Setting Six large HIV treatment centres in southeast England. Participants All individuals seen for care between 1 January 1996 and 31 December 2002. Main outcome measures Exposure to individual antiretroviral drugs and drug classes, CD4 count, plasma HIV RNA burden. Results Information is available on 16 593 individuals (13 378 (80.6%) male patients, 10 340 (62.3%) infected via homosexual or bisexual sex, 4426 (26.7%) infected via heterosexual sex, median age 34 years). Overall, 10 207 of the 16 593 patients (61.5%) have been exposed to any antiretroviral therapy. This proportion increased from 41.2% of patients under follow up at the end of 1996 to 71.3% of those under follow up in 2002. The median CD4 count and HIV RNA burden of patients under follow up in each year changed from 270 cells/mm3 and 4.34 log10 copies/ml in 1996 to 408 cells/mm3 and 1.89 log10 copies/ml, respectively, in 2002. By 2002, 3060 (38%) of patients who had ever been treated with antiretroviral therapy had experienced all three main classes. Of these, around one quarter had evidence of "viral load failure" with all these three classes. Patients with three class failure were more likely to have an HIV RNA burden > 2.7 log10 copies/ml and a CD4 count < 200 cells/mm3. Conclusions The proportion of individuals with HIV infection in the United Kingdom who have been treated has increased gradually over time. A substantial proportion of these patients seem to be in danger of exhausting their options for antiretroviral treatment. New drugs with low toxicity, which are not associated with cross resistance to existing drugs, are urgently needed for such patients.